Combination therapies for treating cancer
A therapy, technology for cancer
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0280] Example 1 - Combination of Low Doses of PARP Inhibiting Agents with Agents Inhibiting PD-1 Signaling Induces Synergistic Antitumor Activity
[0281] Tumor Inoculation and Treatment Protocols
[0282] C57BL / 6 mice were inoculated subcutaneously under the right flank from Apc Min The mSK6005 fragment of a primary murine skin cancer model developed on a / J heterozygous background (R2P4, 2-4 mm in diameter) was used for tumor development. When the average tumor size reaches 148mm 3 At , mice were randomly selected and treatment started.
[0283] Mice were divided into six groups and treated with niraparib, anti-PD-1 (Bio X cells, New Hampshire), vehicle (containing 0.5% methylcellulose), or PD-1 isoforms (Bio X cells, New Hampshire )deal with. Specifically, the treatment regimen for each group is described in Table 2.
[0284] Table 2: Treatment schedule for each group.
[0285]
[0286] All procedures related to animal handling, care, and treatment in this study w...
Embodiment 2
[0288] Example 2 - Treatment of Cancer with Combinations of PARP Inhibitors and Anti-PD-1 Agents
[0289] This Example describes a multicenter, open-label, single-arm Phase 1 / 2 study evaluating the safety and efficacy of combination therapy with a PARP inhibitor (niraparib) and an anti-PD-1 agent (pembrolizumab).
[0290] Inclusion criteria
[0291] To be eligible for this study, patients must have histologically documented advanced (unresectable) metastatic cancer. Specifically, patients with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer, which are exemplary gynecologic cancers, who have recurrent disease and have been previously treated for advanced / metastatic disease, and who respond to First-line platinum-based therapy experiences responses lasting at least 6 months, but is currently considered platinum-resistant and eligible for combination therapy treatment as described herein.
[0292] Administration of Exemplary Agents that Inhibit PARP
[...
Embodiment 3
[0303] Example 3 - Clinical Dose-Discovery Combination Study of PARP Inhibitors and Anti-PD-1 Agents for the Treatment of Cancer
[0304] The following examples describe Phase 1 findings and Phase 2 interim findings of a clinical study designed to evaluate combination therapy with niraparib and an anti-PD-1 agent (pembrolizumab) (TOPACIO; NCT02657889).
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 



